Darrick A Early

Darrick A. Early serves as a Contracting Officer responsible for managing complex acquisitions within the biomedical and pharmaceutical sectors. He plays a critical role in executing federal procurement missions by ensuring compliance with FAR regulations while delivering mission-critical products and services. His portfolio primarily consists of competitive sealed bids and negotiated contracts for biological products, pharmaceutical preparations, and associated laboratory testing services. Early’s expertise lies in navigating the technical and regulatory intricacies of manufacturing and testing requirements under FDA-aligned standards, ensuring acquisitions meet stringent quality and safety benchmarks. While specific contractor relationships are not publicly enumerated, Early’s contracting patterns indicate consistent engagement with manufacturers and testing laboratories possessing GMP and GLP certifications. He routinely collaborates with firms capable of scaling production of sterile injectables, biologics, and active pharmaceutical ingredients, often requiring specialized facility qualifications and supply chain traceability. His procurement approach emphasizes technical capability, regulatory compliance, and performance-based outcomes over price alone, fostering long-term vendor partnerships grounded in reliability and quality assurance. Early’s contracting activity reflects a strong preference for open competition, with 96.7% of awards issued without set-aside restrictions. Only 3.3% of his awards are designated as Total Small Business Set-Asides under FAR 19.5, indicating a targeted but limited use of socioeconomic programs. This suggests a procurement strategy prioritizing technical necessity and supply chain resilience over socioeconomic preferences, though he remains compliant with all applicable small business participation requirements when warranted by market conditions. His primary NAICS focus centers on Biological Product Manufacturing (325414) and Pharmaceutical Preparation Manufacturing (325412), reflecting deep specialization in drug development and biologics production. He also procures testing laboratory services (541380) to support analytical validation and quality control. This technical domain expertise positions him as a key liaison between regulatory science and acquisition execution, ensuring that procured goods meet federal health and safety mandates.